Concepedia

Jonathan W. Goldman

JW

Statistics

Publications

180

Citations

30.3K

H-Index

66

Active since

1981

Affiliations

University of California, Los Angeles(Current)

Memorial Sloan Kettering Cancer Center

Dana-Farber Cancer Institute

The University of Texas MD Anderson Cancer Center

Massachusetts General Hospital

Jonathan W. Goldman is an author at University of California, Los Angeles specializing in oncology, medicine, and pharmacology.

Publications per year

1981–2025

180

Publications

180

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Edward B. Garon, Naiyer A. Rizvi, Rina Hui et al. · New England Journal of Medicine · 2015 · 6.2K citations · Full text

Medicine, Oncology, Pharmacology +17

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet · 2019 · 2.2K citations

Medicine, Oncology, Pharmacology +14

Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer

Yi‐Long Wu, Masahiro Tsuboi, Jie He et al. · New England Journal of Medicine · 2020 · 1.8K citations · Full text

Medicine, Oncology, Pharmacology +15

Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial

Narek Shaverdian, Aaron Lisberg, Krikor Bornazyan et al. · The Lancet Oncology · 2017 · 1.1K citations

Medicine, Oncology, Radiation Oncology +17

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

Matthew D. Hellmann, Naiyer A. Rizvi, Jonathan W. Goldman et al. · The Lancet Oncology · 2016 · 961 citations · Full text

Pharmacy, Oncology, Pharmacology +13

1–5 of 180